《2013 Receptor recognition and cross-species infections of SARS coronavirus》由会员分享，可在线阅读，更多相关《2013 Receptor recognition and cross-species infections of SARS coronavirus（9页珍藏版）》请在金锄头文库上搜索。
1、Review Receptor recognition and cross-species infections of SARS coronavirus Fang Li Department of Pharmacology, University of Minnesota Medical School, Minneapolis, MN 55455, USA a r t i c l ei n f o Article history: Received 26 June 2013 Revised 30 July 2013 Accepted 18 August 2013 Available onlin
2、e 29 August 2013 Keywords: Coronavirus Spike protein Severe acute respiratory syndrome Middle East respiratory syndrome Virus evolution a b s t r a c t Receptor recognition is a major determinant of the host range, cross-species infections, and pathogenesis of the severe acute respiratory syndrome c
3、oronavirus (SARS-CoV). A defi ned receptor-binding domain (RBD) in the SARS-CoV spike protein specifi cally recognizes its host receptor, angiotensin-converting enzyme 2 (ACE2). This article reviews the latest knowledge about how RBDs from different SARS-CoV strains interact with ACE2 from several a
4、nimal species. Detailed research on these RBD/ACE2 interactions has established important principles on host receptor adaptations, cross-species infections, and future evolution of SARS-CoV. These principles may apply to other emerging animal viruses, including the recently emerged Middle East respi
5、ratory syndrome coronavirus (MERS-CoV). This paper forms part of a series of invited articles in Antiviral Research on From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses. ? 2013 Elsevier B.V. All rights reserved. Contents 1.SARS coronavirus . . . . . . . . . . . . . . .
6、 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 246 2.Spike protein and receptor . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7、. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 247 3.Structure of spike protein/receptor complex . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8、248 4.Civet-to-human jump and human-to-human transmission. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 249 5.Adaptations to human or civet receptor. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
9、 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 249 6.Major species barriers between humans and mice, rats or bats . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
10、0 7.Adaptations to mouse receptor . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 250 8.Host range and cross-species infections . . . . . . . . . . . . . . . . . . . .
11、. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 250 9.Structure-based prediction of future evolution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
12、 . . . . . . . . . . . . . . . . 251 10.Comparison with MERS coronavirus. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 252 11.Concluding remarks. . . . . . . . . . . . . . . .
13、 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 252 Acknowledgments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
14、 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 252 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
15、. . . . . . . 252 1. SARS coronavirus The severe acute respiratory syndrome (SARS) epidemic broke out in 20022003 in southern China, and spread to other regions of Asia and also to Europe and North America (Lee et al., 2003; Yu et al., 2004). It caused more than 8000 infections worldwide with an app
16、roximately 10% fatality rate, along with huge economic losses. SARS patients developed fl u-like symptoms, often followed by acute atypical pneumonia and respiratory failure. The epidemic was eventually controlled by conventional public health measures. SARS briefl y re-emerged in 20032004, causing 4 sporadic infec- tions but no fatality or human-to-human transmission (Liang et al., 2004; Song et al., 2005). Since then, there have been no re- ported cases of naturally occurring SARS. Because of
